[HTML][HTML] Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - frontiersin.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
[HTML][HTML] Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu, R Wu - 2023 - cabidigitallibrary.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - europepmc.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …